archive-com.com » COM » H » HBMPARTNERS.COM

Total: 38

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • HBM Partners AG - Press Releases
    therapy in combination with Anti VEGF therapy for wet AMD 209 KB 29 8 2013 Tensys TL 300 receives SFDA approval for Chinese market 68 KB 21 8 2013 Kolltan enters into license and option agreement with MedImmune 289 KB 29 7 2013 PTC Therapeutics closes initial public offering 7 KB 25 6 2013 Basilea awarded contract by BARDA of up to USD 89 million for the development of its novel antibiotic BAL30072 36 KB 25 6 2013 Curetis raises EUR 12 5M in series B 123 KB 22 4 2013 Eye diagnostics innovator i Optics closes EUR 11 8 million financing round 511 KB 02 4 2013 ENANTA PHharmaceuticals announces closing of initial public offering and exercise of underwriters over allotment option 143 KB 26 3 2013 Women s Health Company Gynesonics Completes USD 21 Million Financing Round 290 KB 20 2 2013 Tensys Medical Enters Into Exclusive Commercial Agreement With Zhejiang Shanshi Medical Device For T Line Distribution In China Hong Kong Taiwan 103 KB 12 2 2013 Tensys Medical receives US FDA 510 k for TL 300 latest generation in continuous non invasive hemodynamic patient monitoring system 65 KB 17 1 2013 Latest Portfolio News Eiger BioPharmaceuticals

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2013/news-2013.php (2016-04-25)
    Open archived version from archive


  • HBM Partners AG - Press Releases
    for Hepatitis C programme 103 KB 22 02 2012 Successful IPO of ChemoCentryx 7 KB 09 02 2012 ChemoCentryx licenses rheumatoid arthritis drug to GSK 8 KB 06 01 2012 PTC Therapeutics announces achievement of major milestone in Wellcome Trust BMI1 collaboration 13 KB 11 07 2012 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2012/news.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    31 10 2011 Pacira Pharmaceuticals announces U S FDA approval of EXPAREL TM for postsurgical pain management 26 KB 31 10 2011 ChemoCentryx initiates Phase II clinical trial for CCX168 a novel small molecule C5aR antagonist for the treatment of Vasculitis 56 KB 17 10 2011 Enanta awarded up to 42 7 million niaid contract to develop a novel broad spectrum bicyclolide antibiotic 21 KB 13 10 2011 Nabriva Therapeutics presents extended Phase II results for Pleuromutilin Antibiotic BC 3781 34 KB 15 09 2011 mtm laboratories to be acquired by Roche 120 KB 19 07 2011 Roche acquires mtm laboratories AG expanding offering in cervical cancer testing 74 KB 19 07 2011 Delenex extends its A round to CHF 30 2 million 167 KB 03 05 2011 Nabriva reports positive results from phase II trial of Pleuromutilin antibiotic BC 3781 in ABSSSI 43 KB 18 01 2011 Anthera Pharmaceuticals successfully completes Interim Biomarker analysis of VISTA 16 study and third review of Varespladib Methyl 14 KB 18 04 2011 Mpex Pharmaceuticals Inc to be acquired by Axcan 36 KB 14 04 2011 Pacira Pharmaceuticals Inc announces pricing of its Initial Public Offering 53 KB 03 2 2011 HBM BioVentures Successful sale of indirect holing in China Health System generates cash inflow of approximately USD 17 million 41 KB 01 04 2011 PTC Therapeutics appoints Robert Spiegel M D as Chief Medical Officer 8 KB 30 03 2011 Valeant Pharmaceuticals to acquire PharmaSwis S A 42 KB 01 02 2011 Successful sale of HBM portfolio company PharmaSwiss to Valeant 37 KB 01 02 2011 1 2 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2011/news.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    present positive initial results from phase 2 study in Hepatitis C 57 KB 01 11 2010 Pivotal data suggest PTC Therapeutics Ataluren slows loss of walking ability in muscular distrophy patients 47 KB 15 10 2010 Interventional Spine Inc awarded the 2010 Best New Technology In Cervical Care Award 125 KB 08 10 2010 HBM BioVentures sells its investment in Sloning 39 KB 07 10 2010 Successful sale of Asthmatx a company from HBM BioVentures portfolio to Boston Scientific increases liquidity by CHF 4 million 37 KB 21 09 2010 Nabriva Therapeutic s Pleuromutilin Antibiotic BC 3781 shows therapeutic potential for skin and lung infections with both oral and IV dosing in non clinical and clinical Phase I studies 33 KB 10 09 2010 Vivacta re aligns management in preparation for 4 million finanacing round 24 KB 26 08 2010 Devax receives CE Mark for the AXXESS drug eluting bifurcation stent 30 KB 29 07 2010 HBM BioVentures largest public investment Micrus acquired by Johnson Johnson 38 KB 13 07 2010 HBM Partners to launch new M A Report at BioBusiness Network conference 29 30 September 2010 Geneva 42 KB 30 06 2010 Lux Biosciences names Dean Mitchell President and CEO 24 KB 01 07 2010 Anthera enrolls first patients in pivotal Varespladib phase 3 clinical study 18 KB 23 06 2010 PTC Therapeutics awarded 5 4 million grant from the Wellcome Trust 9 KB 07 06 2010 Nabriva initiates phase II of pleuromutilin antibiotic BC 3781 31 KB 02 06 2010 Mpex Pharmaceuticals presents positive phase 2 clinical trial results of Aeroquin MP 376 treatment in Cystic Fibrosis patients 126 KB 17 05 2010 1 2 Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2010/news.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    severe Asthma 28 KB 28 10 2009 PTC Therapeutics initiates phase 2 clinical trial of Ataluren PTC124 in patients with Hemophilia 12 KB 26 10 2009 Lux Biosciences s potential of LUVENIQ LX211 as first disease modifying treatment for sight threatening non infectious Uveitis highlighted at American Academy of Ophthalmology 70 KB 26 10 2009 Lux Biosciences completes 50 million series B financing 142 KB 19 10 2009 Paratek Pharmaceuticals signs worldwide license and commercialization agreement for PTK 0796 broad spectrum oral and IV antibiotic in phase 3 33 KB 08 10 2009 mtm laboratories extends series C financing round by EUR 7 million bringing total to EUR 39 million USD 57 million 20 KB 05 10 2009 Sloning closes growth financing round led by LBBW Venture 13 KB 25 09 2009 Lux Biosciences reports phase 1 safety results and open label efficacy results for LX214 a potential best in class treament for Dry Eye 33 KB 23 09 2010 HBM Partners successful trade sale of Swiss biotech company ESBATech to Alcon 40 KB 14 09 2009 PTC Therapeutics initiates registration directed Phase 3 trial of Ataluren in Cystic Fibrosis 13 KB 10 09 2009 Mpex Pharmaceuticals announces positive phase 2b clinical trial results with Aeroquin MP 376 treatment in Cystic Fibrosis patients 31 KB 20 09 2009 MiCardia announces completion of enrollment in DYANA European CE study 136 KB 04 09 2009 Successful sale of BRAHMS in an all cash transaction to Thermo Fisher Scientific Net profit for HBM advised antities of EUR 134 2 million or 21 6 times the invested equity 47 KB 03 09 2009 PTC Therapeutics announces achievement of major milestone in Schering Plough Hepatitis C collaboration 9 KB 10 08 2009 Zosana Pharma Inc secures 30 million in new round of financing 25 KB

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2009/news.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Press Releases
    s treatment paradigm published in Nature Medicine 65 KB 28 09 2008 Takeover of public portfolio company CryoCath Technologies 40 KB 26 09 2008 Biovitrum to acquire Kepivance Stemgen and exclusively license 90 KB 15 09 2008 Basilea s Toctino alitretinoin receives first national marketing authorization in the UK 30 KB 08 09 2008 BRAHMS AG Substantial success in the improvement of diagnosis of patients suffering from shortness of breath 65 KB 01 09 2008 Anthera Pharmaceuticals initiates FRANCIS in patients with acute coronary syndrome 72 KB 25 08 2008 Anthera Pharmaceuticals completes 19 million financing 71 KB 13 08 2008 ESBATech raises additional CHF 23M USD 22M extending Series B Venture Financing 74 KB 07 08 2008 Onyx Nexavar approved for liver cancer in China 29 KB 28 07 2008 PTC Therapeutics closes significant cooperation agreement with Genzyme receives 100 million upfront payment 36 KB 17 07 2008 FDA grants conditional approval to Interventional Spine s PercuDyn system IDE application 14 KB 01 07 2008 Basilea s Ceftobiprole a new anti MRSA broad spectrum antibiotic receives its first marketing authorization by Health Canada 35 KB 30 06 2008 Ipsen to acquire Tercica 18 KB 04 06 2008 1 2

    Original URL path: http://www.hbmpartners.com/en/portfolio-news/2008/news.php (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - Contact
    fill in the box First name Please fill in the box Last name Please fill in the box Address Please fill in the box ZIP Code Please fill in the box City Please fill in the box Country Please fill in the box Email Please fill in the box Message The characters you have entered are different from the ones on the screen Title Mrs Mr First name Last name Company Address ZIP Code City Country Email Phone I would like to receive the investor s documentation package I would like to be contacted by an investment advisor Message Security query Please enter the characters you see on the screen into the box reset submit mandatory Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013 29 February 2016 with Morningstar HBM Global Biotechnology Fund is A rated by Citywire for its 3 year risk

    Original URL path: http://www.hbmpartners.com/en/kontakt/index.php?wFormStatus=failed (2016-04-25)
    Open archived version from archive

  • HBM Partners AG - HBM Healthcare Investments
    KIID HBM Global Biotechnology Fund Treuhandvertrag HBM Global Biotechnology Fund Fund Trust Agreement HBM Global Biotechnology Annual Report 2014 Global Biotechnology Fund Semi annual Report 2015 HBM Global Biotechnology Fund HBM Global Healthcare Fund HBM Global Healthcare Fund seeks to generate long term total return by investing in equity and derivatives of healthcare companies globally HBM Global Healthcare Fund Investment Prospectus HBM Global Healthcare Fund Prospekt HBM Global Healthcare Fund Annual Report 2014 HBM Global Healthcare Fund HBM Cobra India HBM Cobra India seeks to generate long term superior return by investing in Indian pharmaceutical companies HBM Panorama Healthcare Fund HBM Panorama Healthcare Fund is an investment opportunity providing you with access to a global and diversified portfolio of investment companies and funds advised by the HBM Partners Team Factsheet HBM Panorama Healthcare Fund Back Latest Portfolio News Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol NASD EIGR as of March 23 Developing a Clinical Stage Pipeline of Orphan Disease Programs Skyepharma to merge with Vectura Group ARMO BioSciences Raises 50 Million Series C Financing Fund Rating HBM Global Biotechnology Fund is rated for its 3 year risk adjusted performance for the period 29 February 2013

    Original URL path: http://www.hbmpartners.com/en/investment-products/hbm-overview-public-equity-investment-funds.php (2016-04-25)
    Open archived version from archive



  •